Description

CJC 1295 without DAC combined with Ipamorelin brings two research peptides together for investigation of growth hormone related signalling pathways. CJC 1295 is a GHRH analogue researched in endocrine pathways, while Ipamorelin is a selective growth hormone secretagogue associated with ghrelin related signalling. The combination provides researchers with a formulation for studying interactions between different peptide signalling mechanisms and endocrine responses. Research may examine growth hormone activity, receptor pathways, and related biological processes under controlled conditions. This formulation contains 5mg of CJC 1295 and 5mg of Ipamorelin, providing 10mg across 10 vials for laboratory research into endocrine and performance related mechanisms.